Alice Yu, MD, PhD
Dr. Yu has more than 40 years of experience in developing cures and understanding the biology of childhood cancer research, has pioneered anti-GD2 therapy, and has either led or significantly contributed in numerous clinical trials to bring novel cancer therapeutics to market.
Mitchell Diccianni, PhD
Dr. Diccianni's focus is on basic research as well as translational biology, where he has been exploiting the unique molecular profiles of cancer cells for tumor cell-selective therapeutic interventions.Read more.
Ayse Batova, PhD
Dr. Batova has been researching the molecular basis of cancer and investigating novel chemotherapeutic agents for more than 20 years. She has validated numerous targets for cancer therapeutics including but not limited to MTAP and GD2.Read more.